Antonio Simeone, COO of Stoneprime, was interviewed in July 2022 by Sole24Ore, Italy’s leading finance and economics magazine.
He spoke about his experience in the field of Biotech, having fully automated the job of scientific researchers with Stoneprime.
By using AI, Stoneprime creates a series of algorithms that assess the potential of over 500 companies in the Biotech sector.
AI analyzes how the market may appreciate new discoveries in relation to the approaching FDA approval, concentrating on the first 3 stages of the process.
Our goal is to improve our algorithms more and more, predicting the Biotech market with ever-increasing accuracy.
Stoneprime provides its financial services to a UCITS fund, and Antonio described its performances related to 2022.
Since its inception, the fund has remained near the top of the Morningstar rankings in the Biotech sector, especially when other funds were losing 30 to 40 percent, with a long-only strategy.
